Dr Sang-Jin Pak Talks Biosimilar Markets: US vs Europe

April 25, 2020

This week on the podcast, we’re speaking with Sang-Jin Pak, MD, the executive vice president of Samsung Bioepis’ Commercial Division.

In April 2020, Samsung Bioepis launched Ontruzant, a biosimilar for trastuzumab, in the US market, in partnership with Merck. The company launched the same drug in Europe in 2018, and it was the first trastuzumab biosimilar in Europe. This earlier release of biosimilars in Europe is not an anomaly, as Europe has had a much easier time developing and launching biosimilars than the US, thanks to their decade-long head start in the industry. We sat down with Sang-Jin Pak, MD, the executive vice president of Samsung Bioepis’ Commercial Division, to discuss the differences between the US and Europe.

To learn more about Samsung Bioepis, visit samsungbioepis.com.


x